Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03167385
Phase
PHASE2
Status
Unknown

Conditions

  • Differentiated Thyroid Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib Mesylate — DRUG
    oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect

Study Details

This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with with locally advanced or metastatic differentiated thyroid carcinoma (DTC). The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with locally advanced or metastatic differentiated thyroid carcinoma.

Key Dates

Start date
Mar 22, 2017
Status verified
Mar 2017
Primary completion
Jan 31, 2019
Completion
Dec 31, 2020

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experitmental
    Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.

Primary Outcome Measure

disease control rate [ Time Frame: within two weeks of drug administration ]

Central Contacts